Patent Wars: GSK Takes on Moderna Over mRNA Innovations

GlaxoSmithKline has filed lawsuits against Moderna in a Delaware federal court, alleging infringement of patents related to mRNA technology in Moderna's COVID-19 vaccine Spikevax and RSV shot mResvia. GSK's actions follow similar litigation against Pfizer. The case underscores ongoing disputes over patent royalties in the pharmaceutical industry.

British pharmaceutical giant GlaxoSmithKline has launched legal action against Moderna, accusing the American company of infringing on GSK's mRNA technology patents.

Filed in a federal court in Delaware, the lawsuits target Moderna's COVID-19 vaccine Spikevax and RSV shot mResvia, claiming patent violations related to lipid nanoparticles used in these products.

This legal move is GSK's latest in a series of patent-related court battles involving Moderna, Pfizer, and BioNTech, highlighting the intense competition and high stakes in the lucrative COVID-19 vaccine market.

(With inputs from agencies.)